Evidence map›Paper›PMID 38868471›Full record

ArticlePCN reports : psychiatry and clinical neurosciences2024

Late-life mood disorder as the initial presentation of progressive supranuclear palsy: A case series.

Kei Ichijo, Keisuke Takahata, Shin Kurose, Takemi Watanabe, Yukihiro Nagase, Hironobu Endo, Kenji Tagai, Makoto Ishitobi, Makoto Higuchi

Abstract read
In one paragraph

Article in PCN reports : psychiatry and clinical neurosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Fourteen years later: Reviewing the diagnostic criteria for behavioral-variant frontotemporal dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kei IchijoTakatsuki Hospital Hachioji Tokyo Japan.ORCID 0000-0002-8815-1326
Keisuke TakahataDepartment of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan.ORCID 0000-0002-0884-4924
Shin KuroseDepartment of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan.
Takemi WatanabeTakatsuki Hospital Hachioji Tokyo Japan.
Yukihiro NagaseTakatsuki Hospital Hachioji Tokyo Japan.
Hironobu EndoDepartment of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan.
Kenji TagaiDepartment of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan.
Makoto IshitobiJinkei Hospital Himeji Hyogo Japan.
Makoto HiguchiDepartment of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Progressive supranuclear palsy (PSP) is a rapidly progressive neurodegenerative disorder characterized by Parkinsonism, supranuclear ophthalmoplegia, postural instability, and cognitive impairment. Patients: This case series describes three patients initially diagnosed with late-life mood disorders (depression and bipolar disorder) who were later diagnosed with PSP because of the development of typical neurological symptoms. Result: The diagnostic challenge of PSP is highlighted in this case report, particularly in the early stages, when characteristic symptoms may not be present. The importance of considering PSP in the differential diagnosis of late-life mood disorders, especially in the absence of response to standard antidepressant therapy, is also emphasized. The heterogeneity of PSP is described, with various subtypes and atypical variants presenting with different clinical features. The psychiatric symptoms of PSP include apathy, disinhibition, depression, and anxiety, whereas hallucinations and delusions are less frequent. Tau positron emission tomography imaging is discussed as a potential biomarker for atypical PSP. Conclusion: Early diagnosis and intervention are crucial for improved outcomes in PSP, necessitating further research to enhance the diagnostic and treatment strategies for PSP and other neurodegenerative diseases.

Indexed as

late‐life mood disorderprogressive supranuclear palsy (PSP)tauopathy

Identifiers

PMID38868471
PMCPMC11114410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.